Skip to main content
. 2019 May 7;10(5):1016–1026. doi: 10.1002/jcsm.12438

Figure 1.

Figure 1

Treatment with RK35 antibody significantly increases body mass in A17 mice: Mice (n = 8–10) were weighed and administered a weekly regimen of either saline or the RK35 antibody (10 mg/kg i.p.) for 10 weeks from the 12th week of age. (A) The average body mass per group plotted against weeks shows that body mass increases in all groups of mice. (B) The average body mass at the final week shows that A17 mice treated with RK35 antibody are heavier than A17 mice treated with saline. TA (C), EDL (D), and soleus (E) were sampled, and mean mass of all muscles were normalized to the initial body mass. Muscle masses of the TA and EDL were increased in both the treated oculopharyngeal muscular dystrophy and control mice, with no change observed in the soleus. Data presented as mean ± standard error of the mean, with P‐values obtained by analysis of variance after a false discovery rate correction (*P < 0.05 and **P < 0.01). EDL, extensor digitorum longus; TA, tibialis anterior.